Anisha Wharton serves as Head of Regulatory Affairs at as Senior Vice President of Marketing at AVEO Oncology, an LG Chem company, and brings more than 16 years of global regulatory leadership to support the development, registration and life-cycle management of biologics and pharmaceutical products. Prior to joining AVEO in 2021, Ms. Wharton served as Director, Global Regulatory Affairs – Oncology at Merck & Co., Inc. where she served as the Global Regulatory Lead for early and late-stage clinical development programs for advanced metastatic tumors, women’s cancers, melanoma, and multiple myeloma. While at Merck, Ms. Wharton led a global regulatory team responsible for the approval of a new dosing regimen of KEYTRUDA® across all approved adult indications in over 35 countries. Prior to Merck, she served in global Regulatory Affairs roles of increasing complexity and responsibility at Nektar Therapeutics, InterMune, Inc. (acquired by Roche), InSite Vision, Inc. (acquired by Sun Pharma), and Genentech, Inc. She helped lead a cross functional team in the approval of ESBRIET® and AZASITE®, as well as the development of a global regulatory intelligence database.  Ms. Wharton earned her Bachelor of Science degree from Clark Atlanta University and her Master of Business Administration degree from the University of San Francisco School of Management.